“IARC o CIRC è acronimo di International Agency for Research on Cancer, o Centre international de Recherche sur le Cancer l’organismo internazionale, con sede a Lione, in Francia, che tra i vari compiti svolti, detta le linee guida sulla classificazione del rischio relativo ai tumori di agenti chimici e fisici. L’agenzia intergovernativa IARC è parte dell’Organizzazione mondiale della sanità OMS, o WHO World Health Organization delle Nazioni Unite.
Lo IARC conserva una serie di monografie sui rischi cancerogeni di svariati agenti.
« IARC’s mission is to coordinate and conduct research on the causes of human cancer, the mechanisms of carcinogenesis, and to develop scientific strategies for cancer control. The Agency is involved in both epidemiological and laboratory research and disseminates scientific information through publications, meetings, courses, and fellowships. »” fonte: http://it.wikipedia.org/wiki/IARC
Dal sito dello IARC, link: http://monographs.iarc.fr/ENG/Classification/crthgr01.php
Overall Evaluations of Carcinogenicity to Humans
Group 1: Carcinogenic to humans
As evaluated in IARC Monographs Volumes 1-99
This list contains all hazards evaluated to date, according to the type of hazard posed and to the type of exposure. Where appropriate, chemical abstract numbers are given [in square brackets]. For details of the evaluation, the relevant Monograph should be consulted (volume number given in round brackets, followed by year of publication of latest evaluation). Use a free-text search to find a particular compound.
Group 1: Carcinogenic to humans (105)
Agents and groups of agents
4-Aminobiphenyl [92-67-1] (Vol. 1, Suppl. 7, Vol. 99; in preparation)
Arsenic [7440-38-2] and arsenic compounds (Vol. 23, Suppl. 7; 1987)
(NB: This evaluation applies to the group of compounds as a whole and not necessarily to all individual compounds within the group)
Asbestos [1332-21-4] (Vol. 14, Suppl. 7; 1987)
Azathioprine [446-86-6] (Vol. 26, Suppl. 7; 1987)
Benzene [71-43-2] (Vol. 29, Suppl. 7; 1987)
Benzidine [92-87-5] (Vol. 29, Suppl. 7, Vol. 99; in preparation)
Benzo[a]pyrene [50-32-8] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
(NB: Overall evaluation upgraded from 2B to 1 based on mechanistic and other relevant data)
Beryllium [7440-41-7] and beryllium compounds (Vol. 58; 1993)
N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornaphazine) [494-03-1] (Vol. 4, Suppl. 7; 1987)
Bis(chloromethyl)ether [542-88-1] and chloromethyl methyl ether [107-30-2] (technical-grade)
(Vol. 4, Suppl. 7; 1987)
1,3-Butadiene [106-99-0] (Vol. 71, Vol. 97; in preparation)
1,4-Butanediol dimethanesulfonate (Busulphan; Myleran) [55-98-1] (Vol. 4, Suppl. 7; 1987)
Cadmium [7440-43-9] and cadmium compounds (Vol. 58; 1993)
Chlorambucil [305-03-3] (Vol. 26, Suppl. 7; 1987)
1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU; Semustine) [13909-09-6] (Suppl. 7; 1987)
Chromium[VI] (Vol. 49; 1990)
Ciclosporin [79217-60-0] (Vol. 50; 1990)
Cyclophosphamide [50-18-0] [6055-19-2] (Vol. 26, Suppl. 7; 1987)
Diethylstilboestrol [56-53-1] (Vol. 21, Suppl. 7; 1987)
Dyes metabolized to benzidine (Vol. 99; in preparation)
(NB: Overall evaluation upgraded to Group 1 based on mechanistic and other relevant data)
Epstein-Barr virus (Vol. 70; 1997)
Erionite [66733-21-9] (Vol. 42, Suppl. 7; 1987)
Estrogen-progestogen menopausal therapy (combined) (Vol. 72, Vol. 91; 2007)
Estrogen-progestogen oral contraceptives (combined) (Vol. 72, Vol. 91; 2007)
(NB: There is also convincing evidence in humans that these agents confer a protective effect against cancer in the endometrium and ovary)
Estrogens, nonsteroidal (Suppl. 7; 1987)
(NB: This evaluation applies to the group of compounds as a whole and not necessarily to all individual compounds within the group)
Estrogens, steroidal (Suppl. 7; 1987)
(NB: This evaluation applies to the group of compounds as a whole and not necessarily to all individual compounds within the group)
Estrogen therapy, postmenopausal (Vol. 72; 1999)
Ethanol [64-17-5] in alcoholic beverages (Vol. 96; in preparation)
Ethylene oxide [75-21-8] (Vol. 60, Vol. 97; in preparation)
(NB: Overall evaluation upgraded from 2A to 1 based on mechanistic and other relevant data)
Etoposide [33419-42-0] in combination with cisplatin and bleomycin (Vol. 76; 2000)
Formaldehyde [50-00-0] (Vol. 88; 2006)
Gallium arsenide [1303-00-0] (Vol. 86; 2006)
[Gamma Radiation: see X- and Gamma (g)-Radiation]
Helicobacter pylori (infection with) (Vol. 61; 1994)
Hepatitis B virus (chronic infection with) (Vol. 59; 1994)
Hepatitis C virus (chronic infection with) (Vol. 59; 1994)
Human immunodeficiency virus type 1 (infection with) (Vol. 67; 1996)
Human papillomavirus types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 66 (Vol. 64, Vol. 90; 2007)
(NB: The HPV types that have been classified as carcinogenic to humans can differ by an order of magnitude in risk for cervical cancer)
Human T-cell lymphotropic virus type I (Vol. 67; 1996)
Melphalan [148-82-3] (Vol. 9, Suppl. 7; 1987)
8-Methoxypsoralen (Methoxsalen) [298-81-7] plus ultraviolet A radiation (Vol. 24, Suppl. 7; 1987)
Methylenebis(chloroaniline) (MOCA) [101-14-4] (Vol. 57, Vol. 99; in preparation)
(NB: Overall evaluation upgraded to Group 1 based on mechanistic and other relevant data)
MOPP and other combined chemotherapy including alkylating agents (Suppl. 7; 1987)
Mustard gas (Sulfur mustard) [505-60-2] (Vol. 9, Suppl. 7; 1987)
2-Naphthylamine [91-59-8] (Vol. 4, Suppl. 7, Vol. 99; in preparation)
Neutrons (Vol. 75; 2000)
(NB: Overall evaluation upgraded from 2B to 1 with supporting evidence from other relevant data)
Nickel compounds (Vol. 49; 1990)
N’-Nitrosonornicotine (NNN) [16543-55-8] and 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) [64091-91-4] (Vol. 37, Suppl. 7, Vol. 89; 2007)
(NB: Overall evaluation upgraded from 2B to 1 based on mechanistic and other relevant data)
[Oestrogen: see Estrogen]
Opisthorchis viverrini (infection with) (Vol. 61; 1994)
[Oral contraceptives, combined estrogen-progestogen: see Estrogen-progestogen oral contraceptives (combined)]
Oral contraceptives, sequential (Suppl. 7; 1987)
Phosphorus-32, as phosphate (Vol. 78; 2001)
Plutonium-239 and its decay products (may contain plutonium-240 and other isotopes), as aerosols (Vol. 78; 2001)
Radioiodines, short-lived isotopes, including iodine-131, from atomic reactor accidents and nuclear weapons detonation (exposure during childhood) (Vol. 78; 2001)
Radionuclides, a-particle-emitting, internally deposited (Vol. 78; 2001)
(NB: Specific radionuclides for which there is sufficient evidence for carcinogenicity to humans are also listed individually as Group 1 agents)
Radionuclides, b-particle-emitting, internally deposited (Vol. 78; 2001)
(NB: Specific radionuclides for which there is sufficient evidence for carcinogenicity to humans are also listed individually as Group 1 agents)
Radium-224 and its decay products (Vol. 78; 2001)
Radium-226 and its decay products (Vol. 78; 2001)
Radium-228 and its decay products (Vol. 78; 2001)
Radon-222 [10043-92-2] and its decay products (Vol. 43, Vol. 78; 2001)
Schistosoma haematobium (infection with) (Vol. 61; 1994)
Silica [14808-60-7], crystalline (inhaled in the form of quartz or cristobalite from occupational sources) (Vol. 68; 1997)
Solar radiation (Vol. 55; 1992)
Talc containing asbestiform fibres (Vol. 42, Suppl. 7; 1987)
Tamoxifen [10540-29-1] (Vol. 66; 1996)
(NB: There is also conclusive evidence that tamoxifen reduces the risk of contralateral breast cancer)
2,3,7,8-Tetrachlorodibenzo-para-dioxin [1746-01-6] (Vol. 69; 1997)
(NB: Overall evaluation upgraded from 2A to 1 with supporting evidence from other relevant data)
Thiotepa [52-24-4] (Vol. 50; 1990)
Thorium-232 and its decay products, administered intravenously as a colloidal dispersion of thorium-232 dioxide (Vol. 78; 2001)
ortho-Toluidine [95-53-4] (Vol. 77, Vol. 99; in preparation)
Treosulfan [299-75-2] (Vol. 26, Suppl. 7; 1987)
Vinyl chloride [75-01-4] (Vol. 19, Suppl. 7, Vol. 97; in preparation)
X- and Gamma (g)-Radiation (Vol. 75; 2000)
Mixtures
Aflatoxins (naturally occurring mixtures of) [1402-68-2] (Vol. 56, Vol. 82; 2002)
Alcoholic beverages (Vol. 44, Vol. 96; in preparation)
Areca nut (Vol. 85; 2004)
(NB: Overall evaluation based on human data, animal data, and mechanistic and other relevant data)
Betel quid with tobacco (Vol. 85; 2004)
Betel quid without tobacco (Vol. 85; 2004)
Coal-tar pitches [65996-93-2] (Vol. 35, Suppl. 7; 1987)
Coal-tars [8007-45-2] (Vol. 35, Suppl. 7; 1987)
Herbal remedies containing plant species of the genus Aristolochia (Vol. 82; 2002)
Household combustion of coal, indoor emissions from (Vol. 95; in preparation)
Mineral oils, untreated and mildly treated (Vol. 33, Suppl. 7; 1987)
Phenacetin, analgesic mixtures containing (Suppl. 7; 1987)
Salted fish (Chinese-style) (Vol. 56; 1993)
Shale-oils [68308-34-9] (Vol. 35, Suppl. 7; 1987)
Soots (Vol. 35, Suppl. 7; 1987)
Tobacco, smokeless (Vol. 37, Suppl. 7, Vol. 89; 2007)
Wood dust (Vol. 62; 1995)
Exposure circumstances
Aluminium production (Vol. 34, Suppl. 7; 1987)
Arsenic in drinking-water (Vol. 84; 2004)
Auramine production (Suppl. 7, Vol. 99; in preparation)
Boot and shoe manufacture and repair (Vol. 25, Suppl. 7; 1987)
Chimney sweeping (Vol. 92; in preparation)
Coal gasification (Vol. 34, Suppl. 7, Vol. 92; in preparation)
Coal-tar distillation (Vol. 92; in preparation)
Coke production (Vol. 34, Suppl. 7, Vol. 92; in preparation)
Furniture and cabinet making (Vol. 25, Suppl. 7; 1987)
Haematite mining (underground) with exposure to radon (Vol. 1, Suppl. 7; 1987)
Involuntary smoking (exposure to secondhand or ‘environmental’ tobacco smoke) (Vol. 83; 2004)
Iron and steel founding (Vol. 34, Suppl. 7; 1987)
Isopropyl alcohol manufacture (strong-acid process) (Suppl. 7; 1987)
Magenta production (Vol. 57, Vol. 99; in preparation)
Painter (occupational exposure as a) (Vol. 47, Vol. 98; in preparation)
Paving and roofing with coal-tar pitch (Vol. 92; in preparation)
Rubber industry (Vol. 28, Suppl. 7; 1987)
Strong-inorganic-acid mists containing sulfuric acid (occupational exposure to) (Vol. 54; 1992)
Tobacco smoking and tobacco smoke (Vol. 83; 2004)
Questa serie di sotanze è stata classificata come sicuramente CANCEROGENA per l’uomo; fra queste fumo di sigaretta, contraccetivi e alcuni farmaci nochè gli incombusti derivati da petrolio (benzo -alpha- pirene).
Se possiamo evitiamole; purtroppo ho visto cosa può portare il cancro.
Non cerchiamocelo., sapendo che può presentarsi anche senza esposizione a cancerogeni.
Doctor Gray's Weblog - Diario di uno Studente di Medicina 